Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
THE BEST BLACK FRIDAY DEAL YET (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Closing prices for crude oil, gold and other commodities
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
THE BEST BLACK FRIDAY DEAL YET (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Closing prices for crude oil, gold and other commodities
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
THE BEST BLACK FRIDAY DEAL YET (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Closing prices for crude oil, gold and other commodities
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
THE BEST BLACK FRIDAY DEAL YET (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Closing prices for crude oil, gold and other commodities

Apellis Pharmaceuticals - APLS Stock Forecast, Price & News

$50.96
+1.47 (+2.97%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$48.87
$51.18
50-Day Range
$43.24
$68.30
52-Week Range
$33.32
$70.00
Volume
555,854 shs
Average Volume
1.96 million shs
Market Capitalization
$5.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.00

Apellis Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
43.2% Upside
$73.00 Price Target
Short Interest
Bearish
8.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$2.63 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.23) to ($5.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

147th out of 1,044 stocks

Pharmaceutical Preparations Industry

60th out of 508 stocks

APLS stock logo

About Apellis Pharmaceuticals (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.

Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Stock News Headlines

See how to make money instead of spending it on Black Friday with this offer
Ph.D. Economist and Investor Nomi Prins is releasing details on her next stunning prediction… It involves “liquid energy” that is promising to trigger an energy revolution 117x bigger than all of the hottest tech trends combined. Even the world’s richest billionaires are investing in the tiny company behind it. And today, you can get in on this cutting-edge financial research at an incredible price tailor-made for Black Friday.
See how to make money instead of spending it on Black Friday with this offer
Ph.D. Economist and Investor Nomi Prins is releasing details on her next stunning prediction… It involves “liquid energy” that is promising to trigger an energy revolution 117x bigger than all of the hottest tech trends combined. Even the world’s richest billionaires are investing in the tiny company behind it. And today, you can get in on this cutting-edge financial research at an incredible price tailor-made for Black Friday.
5 Analysts Have This to Say About Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc - Stock Chart
See More Headlines
Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

APLS Company Calendar

Last Earnings
11/07/2022
Today
11/26/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APLS
Fax
N/A
Employees
476
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$73.00
High Stock Price Forecast
$123.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+43.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
14 Analysts

Profitability

Net Income
$-746,350,000.00
Net Margins
-560.92%
Pretax Margin
-558.72%

Debt

Sales & Book Value

Annual Sales
$66.56 million
Book Value
$2.78 per share

Miscellaneous

Free Float
101,730,000
Market Cap
$5.64 billion
Optionable
Not Optionable
Beta
1.25

Key Executives

  • Dr. Cedric Francois M.D.Dr. Cedric Francois M.D. (Age 50)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $969.54k
  • Dr. Pascal Deschatelets Ph.D.Dr. Pascal Deschatelets Ph.D. (Age 52)
    Co-Founder & Chief Scientific Officer
    Comp: $609.85k
  • Dr. Federico Grossi M.D.Dr. Federico Grossi M.D. (Age 48)
    Ph.D., Co-Founder & Chief Medical Officer
    Comp: $578.01k
  • Mr. Alec Machiels J.D.Mr. Alec Machiels J.D. (Age 49)
    MBA, Co-Founder & Director
    Comp: $72.5k
  • Mr. Timothy E. Sullivan (Age 51)
    CFO & Treasurer
    Comp: $630.17k
  • Mr. Adam J. TownsendMr. Adam J. Townsend (Age 45)
    Chief Commercial Officer
    Comp: $602.69k
  • Ms. Nur Nicholson
    Chief Technical Operations Officer
  • Mr. James G. Chopas CPA (Age 56)
    VP, Corp. Controller & Chief Accounting Officer
  • Ms. Meredith Kaya
    Sr. VP, Investor Relations & Strategic Fin.
  • Mr. David O. Watson Esq.Mr. David O. Watson Esq. (Age 49)
    J.D., Gen. Counsel













APLS Stock - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" APLS shares.
View APLS analyst ratings
or view top-rated stocks.

What is Apellis Pharmaceuticals' stock price forecast for 2023?

14 brokerages have issued 1 year price targets for Apellis Pharmaceuticals' stock. Their APLS share price forecasts range from $40.00 to $123.00. On average, they expect the company's share price to reach $73.00 in the next twelve months. This suggests a possible upside of 43.2% from the stock's current price.
View analysts price targets for APLS
or view top-rated stocks among Wall Street analysts.

How have APLS shares performed in 2022?

Apellis Pharmaceuticals' stock was trading at $47.28 at the beginning of the year. Since then, APLS stock has increased by 7.8% and is now trading at $50.96.
View the best growth stocks for 2022 here
.

When is Apellis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our APLS earnings forecast
.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced its quarterly earnings results on Monday, November, 7th. The company reported ($1.75) EPS for the quarter, missing analysts' consensus estimates of ($1.48) by $0.27. The firm earned $22.06 million during the quarter, compared to analysts' expectations of $19.82 million. Apellis Pharmaceuticals had a negative net margin of 560.92% and a negative trailing twelve-month return on equity of 194.70%.

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.17%), BlackRock Inc. (6.41%), Price T Rowe Associates Inc. MD (3.03%), State Street Corp (2.67%), Jennison Associates LLC (2.31%) and Cormorant Asset Management LP (1.34%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Pascal Deschatelets, Victoria L Brown and Victoria L Brown.
View institutional ownership trends
.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $50.96.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals (NASDAQ:APLS) has a market capitalization of $5.63 billion and generates $66.56 million in revenue each year. The company earns $-746,350,000.00 in net income (profit) each year or ($6.24) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

The company employs 476 workers across the globe.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The official website for the company is www.apellis.com. The company can be reached via phone at (617) 977-5700 or via email at investors@apellis.com.

This page (NASDAQ:APLS) was last updated on 11/26/2022 by MarketBeat.com Staff